publication date: Feb. 3, 2014
20140203 - Feb. 3, 2014
JANUARY 2014PDF

Pancreatic Cancer

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

A phase III trial of Abraxane extended overall survival in metastatic pancreatic cancer, with some patients surviving longer than three years, when used in combination with gemcitabine. 

The updated OS data from the Metastatic Pancreatic Adenocarcinoma Clinical Trial was presented at the American Society of Clinical Oncology Gastrointestinal Conference in San Francisco. 

Leukemia
Phase III Trial of Imbruvica Halted, Following
Increases in Progression-Free Survival

A phase III study of Imbruvica in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma was stopped early following an interim analysis and at the recommendation of an independent data monitoring committee, which concluded the study demonstrated a significant difference in progression-free survival compared to ofatumumab.

Breast Cancer
Long-term Follow-up Shows ADH and ALH Tissue
Abnormalities Can Carry Similar Risk

Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.

Kidney Cancer
Patients on Hypertension Meds Lived Longer, Analysis Shows
Liver Cancer
Post-Hoc Analysis of ThermoDox Suggests OS Improvement
Prostate Cancer
Study: Gene Assay Can Provide Valid Prognostic Information
Colon Cancer
Studies of Oncotype DX Test Presented at ASCO Symposium
Lung Cancer
MicroRNA Assay Detects Cancer Two Years Before LDCT in Study
NCI Approved Trials for the Month of January
FDA News

  • Accelerated Approval granted to Mekinist-Tafinlar combination in unresectable or metastatic melanoma

  • 510(k) Clearance granted to spectral breast density measurement application

  • Reagent system approved for prevention of graft-versus-host disease

  • FDA launches advisory committee membership nomination web portal
  • Orphan drug designation granted to BL-8040 as a treatment for stem cell mobilization
  • FDA lifts clinical hold on tosedostat
  • And more…

Copyright (c) 2020 The Cancer Letter Inc.